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Introduction: The role of trimodality therapy for locally advanced
non-small cell lung cancer (NSCLC) continues to be defined. We
hypothesized that imaging parameters on pre- and postradiation
positron emission tomography (PET)-computed tomography (CT)
imaging are prognostic for outcome after preoperative chemoradio-
therapy (CRT)/resection/consolidation chemotherapy and could help
risk-stratify patients in clinical trials.
Methods: We enrolled 13 patients on a prospective clinical trial of
trimodality therapy for resectable locally advanced NSCLC.
PET-CT was acquired for radiation planning and after 45 Gy. Gross
tumor volume (GTV) and standardized uptake value were measured
at pre- and post-CRT time points and correlated with nodal patho-
logic complete response, loco-regional and/or distant progression,
and overall survival. In addition, we evaluated the performance of
automatic deformable image registration (ADIR) software for vol-
umetric response assessment.
Results: All patients responded with average total GTV reductions
after 45 Gy of 43% (range: 27–64%). Pre- and post-CRT GTVs
were highly correlated (R2  0.9), and their respective median
values divided the patients into the same two groups. ADIR mea-
surements agreed closely with manually segmented post-CRT
GTVs. Patients with GTV  median (137 ml pre-CRT and 67 ml
post-CRT) had 3-year progression-free survival (PFS) of 14% ver-
sus 75% for GTV less than median, a significant difference (p 
0.049). Pre- and post-CRT PET-standardized uptake value did not
correlate significantly with pathologic complete response, PFS, or
overall survival.
Conclusions: Preoperative CRT with carboplatin/docetaxel/45 Gy
resulted in excellent response rates. In this exploratory analysis, pre-
and post-CRT GTV predicted PFS in trimodality therapy, consistent
with our earlier studies in a broader cohort of NSCLC. ADIR seems
robust enough for volumetric response assessment in clinical trials.
Key Words: Lung cancer, Trimodality therapy, Volumetric re-
sponse assessment, Automatic deformable image registration, Pos-
itron emission tomography-computed tomography (PET-CT).
(J Thorac Oncol. 2011;6: 920–926)
Lung cancer is a devastating global epidemic responsiblefor approximately 160,000 deaths annually in the United
States and 1.4 million worldwide.1,2 In the United States,
approximately 25% of patients are diagnosed with locally
advanced disease,1 representing the majority of those who are
potentially curable. The optimal treatment for patients with
stage III non-small cell lung cancer (NSCLC) is controver-
sial, particularly in stage IIIA for which diverse treatment
strategies are used. In general, the most standard treatment is
definitive concurrent chemoradiotherapy (CRT).3 It is likely,
however, that properly selected patients would benefit from
an intensified treatment approach that includes surgical
resection.
The European Organization for the Treatment of Can-
cer Lung Cancer Group conducted a trial in which patients
with pathologically proven stage IIIA(N2) NSCLC who re-
sponded to induction chemotherapy were randomized to ra-
diation therapy versus surgical resection, finding no signifi-
cant difference in overall survival (OS) or progression-free
survival (PFS) between the arms.4 Similarly, the North Amer-
ican Intergroup INT0139 trial randomized patients with
pathologically proven stage IIIA(N2) NSCLC between more
intensive regimens consisting of trimodality therapy, i.e.,
preoperative CRT followed by surgical resection, versus
definitive CRT, again finding no significant difference in OS
between the arms. Nevertheless, an exploratory subgroup
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analysis suggested that patients resectable by lobectomy
rather than pneumonectomy might have improved survival
with the trimodality approach.5 In both studies, mediastinal
pathologic complete response (pCR) after preoperative ther-
apy was a strongly positive prognostic factor.
Predictive factors that identify patients who are likely
to benefit from trimodality therapy would be valuable tools
for individualized therapy selection, especially if they can be
determined noninvasively. We hypothesized that imaging
parameters derived from combined positron emission tomog-
raphy-computed tomography (PET-CT) scans performed pre-
and post-CRT administered as part of a trimodality regimen
for stage III NSCLC, including tumor volume and standard-
ized uptake value (SUV), would correlate with survival
outcomes (OS and PFS). We performed this as a planned
secondary analysis of a prospective phase II clinical trial, the
primary results of which are reported separately. As an
ancillary analysis, we also evaluated whether automated de-
termination of tumor volumes after preoperative CRT corre-
lates with manually determined tumor volumes and could,
thus, facilitate response measurements and risk stratification
in the clinical trials setting.
PATIENTS AND METHODS
Treatment
From July 2003 to January 2009, 13 patients were
enrolled in an institutional review board-approved phase II
clinical trial of preoperative CRT, resection, and consolida-
tion chemotherapy for resectable stage IIIA/IIIB NSCLC at
Stanford University and Cancer Center. Patients were eligible
if they had untreated, resectable, and pathologically con-
firmed stage IIIA or IIIB NSCLC. After signing informed
consent, all patients received preoperative CRT consisting of
weekly carboplatin (area under the curve of 2) and docetaxel
(20 mg/m2) concurrent with radiotherapy to a dose of 45 Gy
in 1.8 Gy fractions. The treatment volume included the
primary tumor, ipsilateral hilar nodes, and ipsilateral medi-
astinal nodes. Surgical resection was performed 3 to 6 weeks
after CRT and consisted of lobectomy or bilobectomy with
mediastinal nodal sampling or dissection. Surgery was fol-
lowed by three cycles of consolidation chemotherapy with
carboplatin (area under the curve of 6) and docetaxel (75
mg/m2) given with growth factor support.
Pre- and Post-CRT Tumor Volume
Standard [18F]-fluoro-2-deoxyglucose whole body PET
and CT of the thorax was obtained for each patient before
initiation of therapy, in several cases as the radiation treat-
ment planning scan. Repeat PET-CT was required at com-
pletion of preoperative CRT, before surgical resection. All
imaging studies were available for volumetric analysis.
The structures of interest were delineated on treatment
planning scans by radiation oncologists experienced in tho-
racic radiation therapy (B.W.L. and Q.-T.L.). Treatment plan-
ning scans with associated structure sets were exported from
the treatment planning system to the automatic deformable
image registration (ADIR) software, MIMcontouring Ad-
vanced (MIMvista Corp., Cleveland, OH). This commercial
software uses a proprietary intensity-based free-form deform-
able CT-to-CT image registration algorithm that uses regu-
larization to minimize folds and tears in the deformation
fields.6 After initial rigid registration of the CT component of
the pre- and post-CRT scans, contours from the pre-CRT
structure sets were automatically deformed onto the post-
CRT scans. Automatically deformed contours were then
corrected manually (M.M.K.) and independently verified by
an experienced thoracic radiation oncologist (B.W.L.). Pri-
mary and nodal gross tumor volume (GTV) were segmented
separately and calculated at pre- and post-CRT time points
and the absolute and relative change between them calcu-
lated. These parameters were correlated with loco-regional
and/or distant progression, and OS. ADIR and manually
corrected post-CRT tumor volumes were compared.
Analysis of PET and Pathologic Nodal
Response
All patients underwent nodal sampling or dissection at
time of surgery. Pathology reports were analyzed, and the
sampled nodal stations were scored for each patient as posi-
tive or negative for malignancy. In addition, an experienced
nuclear radiologist (M.L.S.) blinded to the pathology results
scored all mediastinal lymph node stations as positive, equiv-
ocal, or negative on both pre- and post-CRT PET-CT scans.
PET imaging parameters were correlated with pathologic
response in all sampled nodal stations.
Statistics
Survival curves were constructed using the method of
Kaplan and Meier.7 PFS and OS were calculated from the
date of the post-CRT PET-CT scan, the timing of which was
the most consistent across all the patients. An event for PFS
was defined as evidence of disease progression (local or
distant) or death from any cause, whichever came first.
Volumetric endpoints analyzed include pre-CRT GTV, post-
CRT GTV, absolute change in GTV, and relative change in
GTV. These endpoints were stratified by their median values,
and differences in outcome (PFS and OS) were assessed with
a log-rank test. PET parameters analyzed were maximum and
mean SUV. All these parameters were determined for pri-
mary tumor, abnormal nodes, and total (primary plus nodes).
Linear regression was used to determine the relationship
between pre- and post-CRT GTV and also the relationship
between ADIR and manually corrected post-CRT GTV. Sta-
tistical analysis was done with SAS version 9.2 (SAS Insti-
tute Inc., Cary, NC).
RESULTS
Patient Characteristics
The patient characteristics are summarized in Table 1.
Median age was 63 years (range: 39–82). All patients had
biopsy-proven N2 disease. Seven patients had a diagnosis of
adenocarcinoma, four of squamous cell carcinoma, one of
large cell neuroendocrine carcinoma, and one of NSCLC not
otherwise specified. Only one patient did not undergo resec-
tion, as the treating surgeon felt the patient was not optimally
resectable after preoperative CRT. The patient then com-
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pleted definitive CRT to 61 Gy and consolidation chemother-
apy per protocol. The median time from the pre-CRT
PET-CT scan to initiation of CRT was 28 days (range: 6–50
days). The median time from completion of CRT to the
post-CRT PET-CT scan was 0 days (range: 3 days before
completion of CRT to 5 days after).
Overall Outcomes
A detailed analysis of the primary clinical outcomes
and toxicities of this trial is published separately.8 Median
follow-up from date of the post-CRT scan was 25 months
overall and 39 months in living patients (range: 11–55
months). OS and PFS were 72% and 36%, respectively, at 2
years, and 62% and 36%, respectively, at 3 years. Median OS
and PFS were not reached and 21 months, respectively. No
patients died before cancer progression. Eight patients remain
alive at last follow-up, and of these, six have no evidence of
disease, and one more has no evidence of disease after
treatment of an isolated brain metastasis.
Table 2 summarizes the imaging parameters and out-
comes in each patient.
Volumetric Response and Performance of ADIR
Response Assessment
All patients responded with total GTV reductions after
45 Gy of 43% on average (range: 27–64%) (Figure 1). Given
the mean treatment time of 35 days, this corresponds to a
mean volume reduction rate of 1.23%/d. In addition, pre- and
post-CRT volumes were highly correlated (R2  0.91) indi-
cating a consistent degree of volumetric response across the
patient cohort (Figure 2). The same degree of volume reduc-
tion of approximately 40% was observed for the total GTV,
primary GTV, and nodal GTV based on the slopes of the
corresponding regression lines (0.62, 0.58, and 0.63, respec-
tively). Because of the high correlation, dividing the patient
cohort by the median of the pre-CRT GTV (below or above
137 ml) or the post-CRT GTV (below or above 68 ml)
produced the same two groups of patients.
The post-CRT GTVs determined by ADIR were highly
correlated with the manually edited post-CRT GTVs (R2 
0.97, slope  1.02) but slightly overestimated the total GTV
by 13 ml on average (Figure 3). Thus, dividing the patient
cohort by the median of ADIR-based post-CRT GTV (below
or above 94 ml) or the manually edited post-CRT GTV
(below or above 68 ml) also produced the same two groups of
patients.
Patients with total GTV  median (of pre-CRT or
post-CRT GTV, automatically or manually segmented) had
2- and 3-year PFS of 14% compared with 75% for GTV less
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1 50.2 17.9 41.2 13.2 24.2 6.4 9.0 4.7 3.0 3.5 11.1 11.1
2 60.3 34.1 41.9 23.8 6.5 2.8 18.4 10.3 4.0 3.2 41.1 41.1
3 26.2 16.3 20.3 12.5 19.0 10.5 5.9 3.8 7.4 3.6 13.0 13.0
4 171.2 86.3 146.0 76.0 16.1 19.5 25.2 10.3 8.4 2.9 8.2* 41.4
5 153.1 73.9 143.4 65.9 11.6 14.4 9.8 8.0 5.5 5.0 21.0* 36.5
6 301.6 209.1 266.0 180.1 20.6 13.4 35.6 28.9 5.8 6.0 11.0* 22.6*
7 44.8 28.9 2.9 1.9 1.4 2.2 41.9 27.0 4.6 8.0 46.1 46.1
8 270.5 108.4 256.3 101.3 16.4 4.3 14.1 7.1 8.9 2.1 20.5* 25.5*
9 323.2 208.6 236.8 146.6 3.9 7.3 86.5 62.0 2.4 7.5 4.2* 12.5*
10 137.4 67.6 66.8 36.2 21.4 5.1 70.6 31.4 8.7 3.7 7.1* 15.2*
11 238.8 166.2 211.5 142.1 22.3 13.2 27.3 24.1 4.7 2.5 54.7 54.7
12 59.4 43.2 11.9 10.7 6.5 4.2 47.5 32.5 4.7 3.5 13.8* 36.0*
13 69.4 38.8 62.5 34.6 13.4 4.8 6.9 4.2 5.6 2.2 18.7 18.7
Mean  SD 147  106 85  69 116  99 65  60 14  7.6 8.3  5.3 31  25 20  17 5.7  2.1 4.1  1.9 21a NRa
a In shaded boxes, Kaplan-Meier estimated median progression-free survival and overall survival.
NR, not reached; GTV, gross tumor volume; CRT, chemoradiotherapy; SUV, standardized uptake value.
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than median (p  0.049) (Figure 4A). When broken down
into primary and nodal GTV, PFS most strongly correlates
with primary GTV (p  0.049) and not nodal GTV (p 
0.31). There is a trend toward an OS difference between total
GTV below or above the median value that does not reach
statistical significance (p  0.31) (Figure 4B).
Pathologic Nodal Response
A total of 49 nodal stations were sampled in 12 pa-
tients. Of those, eight stations were pathologically positive
FIGURE 1. Volumetric response to preoperative chemoradiotherapy (CRT) in a patient with stage IIIA non-small cell lung
cancer (NSCLC; patient 8). A, a representative axial, saggital, and coronal cut through the gross tumor volume (GTV), includ-
ing primary and nodal disease, outlined in red. The contours were manually delineated as part of the radiation planning pro-
cess. B, substantial (60%) volume reduction in the GTV after CRT (45 Gy). The post-CRT contours (red) were generated from
the pre-CRT contours using automatic deformable image registration (ADIR). Only minimal further manual editing was re-
quired to produce the final post-CRT contours.
FIGURE 2. Comparison of pre- and postchemoradiotherapy
(CRT) tumor volumes (total, primary, and nodal). Solid line:
regression line for total tumor volume. The high correlation
indicates a consistent response to CRT of approximately
40% volume reduction. Dotted line: identity line corre-
sponding to no volumetric response. Vertical and horizontal
dashed lines: median values of pre- and post-CRT total tu-
mor volumes, respectively, each of which divide the patient
cohort into the same two subgroups.
FIGURE 3. Comparison of postchemoradiotherapy (CRT) tu-
mor volumes (total, primary, and nodal) determined by man-
ual editing versus automatic deformable image registration
(ADIR). Solid line: regression line for total tumor volume. Dot-
ted line: identity line corresponding to perfect agreement. The
high correlation and slope of near unity indicate good agree-
ment between ADIR and manually edited volumes (the gold
standard), but the offset indicates a slight consistent overesti-
mation by ADIR of approximately 13 ml. Vertical and horizon-
tal dashed lines: median values of manual and ADIR total tu-
mor volumes, respectively, each of which divide the patient
cohort into the same two subgroups.
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and 41 were negative after CRT. The pre- and post-CRT PET
scores are tabulated by pathologic status in Table 3 (with a
total of three stations with equivocal scores on PET counted
as positive). On a per nodal station basis, sensitivity, speci-
ficity, positive predictive value, negative predictive value,
and accuracy of PET were 0.75, 0.8, 0.43, 0.94, and 0.8,
respectively, for pre-CRT imaging, and 0.5, 0.93, 0.57, 0.9,
and 0.86, respectively, for post-CRT imaging. On a per
patient basis, all patients had PET-positive nodes pre-CRT,
and post-CRT sensitivity, specificity, PPV, NPV, and accu-
racy were all 0.67.
Other Correlates
Change between pre- and post-CRT total GTV,
whether absolute or relative (percent of pre-CRT value), did
not seem to correlate with PFS (p  0.18 and p  0.39,
respectively) or OS (p  0.78 and p  0.96, respectively).
Pre-CRT PET SUVmax and SUVmean values did not correlate
significantly with PFS (p  0.48 and p  0.14, respectively)
or OS (p  0.50 and p  0.50, respectively). Post-CRT
SUVmax and SUVmean did not correlate significantly with PFS
(p  0.57 and p  0.056, respectively) or OS (p  0.77 and
p  0.39, respectively). Nodal pCR was achieved in six
patients (50% of resected patients). Nevertheless, pCR was
not significantly associated with improved PFS (p  0.55) or
OS (p  0.87).
DISCUSSION
A clear limitation of this study is its small size, reflect-
ing patterns of referral to our institution and stringent selec-
tion criteria. As such, however, it is notable for the relative
uniformity of the patient cohort in that all had a high perfor-
mance status and a low volume of nodal tumor burden
relative to the primary tumor volume but with a representa-
tive mix of NSCLC histologies. This represents the patient
population generally considered the most appropriate candi-
dates for trimodality therapy. Although it is hard to draw
strong conclusions owing to the small sample size, a few
striking observations stand out from this analysis.
First is the surprising uniformity across the patient
group of volumetric response to preoperative CRT using a
modest radiation dose of 45 Gy, averaging more than 40%
volume reduction (or 1.2%/d) for primary, nodal, and total
tumor volume, with significant volumetric responses in all
patients (Figure 2). By comparison, several small, mostly
retrospective studies (of 8–25 patients) have analyzed the
degree of volumetric response in patients with a mixture of
NSCLC stages (I–IV, most patients with stage III) treated
with radiotherapy (mostly definitive, most with conventional
fractionation) with or without chemotherapy (sequential or
concurrent).9–16 These studies demonstrated variable volu-
metric responses between series, some with only a minority
FIGURE 4. When stratified by the median value of total tumor volume (whether prechemoradiotherapy [CRT] or post-CRT
determined by either manual editing or automatic deformable image registration [ADIR]), patients with lower tumor volume
had significantly improved progression-free survival (PFS), and a statistically insignificant trend toward improved overall sur-
vival. A, PFS by tumor volume. B, Overall survival (OS) by tumor volume.
TABLE 3. Correlation between PET and Pathologic Nodal Clearance
Pre-CRT PET (per Nodal Station) Post-CRT PET (per Nodal Station) Post-CRT PET (per Patient)
Path  Path  Total Path  Path  Total Path  Path  Total
PET  6 8 14 PET  4 3 7 PET  4 2 6
PET  2 33 35 PET  4 38 42 PET  2 4 6
Total 8 41 49 Total 8 41 49 Total 6 6 12
PET, positron emission tomography; CRT, chemoradiotherapy.
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of patients having volume reductions of more than 25 to
30%10,11 and most with more consistent responses (averaging
38–73% volume reduction) as seen in our study. In the study
most similar to our study, 13 patients with stage IIIA/B
NSCLC treated on a prospective trial with definitive CRT
using concurrent cisplatin/docetaxel and 60 to 67.2 Gy in 30
fractions had a mean tumor volume reduction of 73% (range:
41–100%) at the end of concurrent CRT or a mean volumetric
response rate of 1.7%/d, a result very consistent with ours
considering the difference in radiation dose and fraction-
ation.16 Our study is notable for its prospective design and the
substantial responses achieved with only a modest preopera-
tive dose of radiotherapy (45 Gy in 1.8 Gy fractions). These
data may indicate the activity of the platinum/docetaxel
regimen when administered concurrently with radiation.
Second, despite our small study size, a statistically
significant correlation between tumor volume and PFS was
demonstrated, suggesting that its effect may be a large one.
Interestingly, because of the uniformity of the response, pre-
and post-CRT tumor volumes were equally prognostic. The
prognostic impact of pretreatment GTV has been demon-
strated in several studies of patients with NSCLC treated with
definitive radiotherapy with or without concurrent chemo-
therapy.17–24 These studies found that tumor volume is inde-
pendently and highly prognostic for PFS/local control and in
most cases OS, often exceeding the impact of stage, radiation
dose, and other conventional prognostic factors.
We did not find PET SUV parameters to be signifi-
cantly correlated with outcomes possibly reflecting their
smaller effect compared with tumor volume, such that a study
of this size cannot detect it. This is consistent with our
previous studies demonstrating that pretreatment metabolic
tumor volume (i.e., the volume of metabolically active tumor
burden on PET-CT) but not SUV was significantly prognostic
for PFS and OS in a broadly selected cohort of patients with
NSCLC, again reflecting the larger impact of tumor vol-
ume,25,26 assessed in this study as GTV. On the other hand,
although we did not find it in this study, we and others have
found that SUV on PET-CT acquired partway through a
course of definitive CRT may predict progression indepen-
dent of other prognostic factors.27–29
PET-CT also failed to predict nodal pCR to preopera-
tive CRT in our study. This is consistent with the findings of
a recent systematic review suggesting that existing imaging
and minimally invasive assessments of nodal response are
rather poorly reliable.30 Nevertheless, unlike other studies of
preoperative therapy,4,5 we did not find pCR status to be
prognostic, possibly owing to our small study size.
A technical challenge of conducting studies of volu-
metric response is the need for manual segmentation of tumor
volumes on serial imaging studies, a tedious and time con-
suming task that requires expertise in anatomy and image
interpretation. As this is done as part of modern three-
dimensional radiation treatment planning on pretreatment
scans, studies analyzing the prognostic significance of tumor
volume tend to involve cohorts treated with radiation therapy.
Studies of volumetric response additionally require recon-
touring serial scans, which is impractical for routine practice
without the assistance of automated software tools. ADIR has
become available to facilitate adaptive radiation therapy re-
planning. Its intended use in that context is to produce an
initial set of contours sufficiently accurate that editing them is
less time consuming than recontouring from scratch. Manual
editing should be considered mandatory for highly conformal
radiotherapy planning,31 and indeed we found that ADIR
slightly overestimated the post-CRT tumor volumes, possibly
because the starting point for the deformation was the often
much larger pre-CRT volume. Nevertheless, manual editing
may not be necessary for the less stringent function of risk
stratification, for example, in the clinical trial setting. Our
observations that ADIR-determined tumor volumes are
highly correlated with manually edited volumes and stratify
the patient cohort into the same subgroups (Figure 3) suggest
that ADIR alone is sufficiently robust for volumetric response
assessment in clinical trials and may make trials with such an
endpoint feasible to conduct, while eliminating the interob-
server variability inherent in manual tumor delineation,
which is particularly an issue in multicenter trials.
In conclusion, preoperative CRT with carboplatin/do-
cetaxel/45 Gy resulted in excellent response rates, suggesting
a high activity of this regimen across NSCLC histologies. We
were unable to identify a predictive association of SUV in
pre- and post-CRT [18F]-fluoro-2-deoxyglucose-PET imag-
ing. Pre- and post-CRT GTV may predict PFS in trimodality
therapy and could potentially be used to identify patients
most likely to do well with this treatment approach. We do
not have the data to address whether GTV might be used to
select patients for trimodality therapy versus definitive CRT,
as low GTV correlates with better outcomes with either
approach. Nevertheless, our data support the use of tumor
volume as a factor for risk stratification in clinical trials
comparing treatment strategies for locally advanced NSCLC.
ADIR may be a valuable tool for volumetric response assess-
ment in clinical trials.
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